BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27764253)

  • 21. Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.
    Cottin L; Riou J; Orvain C; Ianotto JC; Boyer F; Renard M; Truchan-Graczyk M; Murati A; Jouanneau-Courville R; Allangba O; Mansier O; Burroni B; Rousselet MC; Quintin-Roué I; Martin A; Sadot-Lebouvier S; Delneste Y; Chrétien JM; Hunault-Berger M; Blanchet O; Lippert E; Ugo V; Luque Paz D
    Br J Haematol; 2020 Mar; 188(6):935-944. PubMed ID: 31710700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
    Tang Q; Zhang XW; Xia L; Jiang NK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
    Belcic Mikic T; Pajic T; Sever M
    Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CALR mutation profile in Irish patients with myeloproliferative neoplasms.
    Haslam K; Conneally E; Flynn CM; Cahill MR; Gilligan O; O'Shea D; Langabeer SE
    Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):112-5. PubMed ID: 27352261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Application of genetic data to clinical practice of MPN].
    Edahiro Y
    Rinsho Ketsueki; 2015 Aug; 56(8):949-55. PubMed ID: 26345552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New disease markers within the chronic myeloproliferative neoplasms].
    Holmström MO; Ocias LF; Kallenbach K; Kjær L; Kristensen TK; Pallisgaard N; Petersen BL; Skov V; de Stricker K; Larsen TS; Hasselbalch HC
    Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
    Wang J; Hao J; He N; Ji C; Ma D
    Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rare CALR variant mutation and efficient peginterferon alfa-2a response in a patient with essential thrombocythemia.
    Ciftciler R; Balasar O
    Cancer Genet; 2023 Jun; 274-275():51-53. PubMed ID: 36972657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Detection of ASXL1 Mutation and CALR Mutation Coexistance in Patients with Ph Negative Myeloproliferative Neoplasm and Its Clinical Gignificance].
    Chen MY; Shen HJ; Chao HY; Zhou M; Lu XZ; Zhang XW; Liu J; Jiang NK; Wang Q
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1738-1743. PubMed ID: 29262908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
    Martin S; Wright CM; Scott LM
    Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of
    Kim HY; Han Y; Jang JH; Jung CW; Kim SH; Kim HJ
    Diagnostics (Basel); 2022 Oct; 12(11):. PubMed ID: 36359414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diversities of Calreticulin Gene Mutations in Macedonian Patients With Essential Thrombocythemia.
    Panovska-Stavridis I; Eftimov A; Ivanovski M; Stojanovic A; Georgievski B; Cevreska L; Dimovski AJ
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):477-81. PubMed ID: 27521277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
    Pietra D; Rumi E; Ferretti VV; Di Buduo CA; Milanesi C; Cavalloni C; Sant'Antonio E; Abbonante V; Moccia F; Casetti IC; Bellini M; Renna MC; Roncoroni E; Fugazza E; Astori C; Boveri E; Rosti V; Barosi G; Balduini A; Cazzola M
    Leukemia; 2016 Feb; 30(2):431-8. PubMed ID: 26449662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.
    Czech J; Cordua S; Weinbergerova B; Baumeister J; Crepcia A; Han L; Maié T; Costa IG; Denecke B; Maurer A; Schubert C; Feldberg K; Gezer D; Brümmendorf TH; Müller-Newen G; Mayer J; Racil Z; Kubesova B; Knudsen T; Sørensen AL; Holmström M; Kjær L; Skov V; Larsen TS; Hasselbalch HC; Chatain N; Koschmieder S
    Leukemia; 2019 Apr; 33(4):995-1010. PubMed ID: 30470838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Myeloproliferative neoplasms: revisions in the 2016 WHO criteria].
    Hidaka T; Kamiunten A; Shimoda K
    Rinsho Ketsueki; 2018; 59(8):1066-1071. PubMed ID: 30185707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A rare CALR variant mutation and a review of CALR in essential thrombocythemia.
    Diep R; Metjian A
    J Thromb Thrombolysis; 2018 Apr; 45(3):457-462. PubMed ID: 29411299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.
    Alvarez-Larrán A; Sant'Antonio E; Harrison C; Kiladjian JJ; Griesshammer M; Mesa R; Ianotto JC; Palandri F; Hernández-Boluda JC; Birgegård G; Nangalia J; Koschmieder S; Rumi E; Barbui T
    Lancet Haematol; 2021 Sep; 8(9):e658-e665. PubMed ID: 34450103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing.
    Rahman K; Chandra D; Singh MK; Gupta R; Sharma A; Paul P; Kumar S; Sharma S; Nityanand S
    Int J Lab Hematol; 2020 Oct; 42(5):604-611. PubMed ID: 32463176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis.
    Kong H; Liu Y; Luo S; Li Q; Wang Q
    Intern Med; 2016; 55(15):1977-84. PubMed ID: 27477402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.